Abstract | BACKGROUND: PATIENTS AND METHODS: Our 6-month prospective observation study used a randomized control and open-label design as we examined the effects of an ARB ( valsartan) on blood pressure, urinary albumin excretion, hematocrit, serum potassium and estimated glomerular filtration rate (eGFR) in normotensive recipients with allografts of more than 1 year. A total of 35 renal transplant recipients were enrolled in this study. Patients were randomly assigned to 2 groups: ARB group (n=18), receiving 40-80 mg valsartan daily for 6 months, and the control group (n=17). RESULTS: In the ARB group, urine albumin excretion was significantly reduced from 25.9 ± 19.1 mg/g to 12.0 ± 9.6 mg/g at 6 months after administration. eGFR decreased slightly at 6 months after administration. However, no patients undergoing treatment for adverse effects required discontinuation of ARB. CONCLUSIONS:
|
Authors | Junji Uchida, Yuichi Machida, Tomoaki Iwai, Taro Iguchi, Yoshiko Kamada, Toshihide Naganuma, Norihiko Kumada, Taku Kim, Hidenori Kawashima, Tatsuya Nakatani |
Journal | Journal of nephrology
(J Nephrol)
2011 Jul-Aug
Vol. 24
Issue 4
Pg. 515-21
ISSN: 1724-6059 [Electronic] Italy |
PMID | 21240871
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Angiotensin II Type 1 Receptor Blockers
- Tetrazoles
- Valsartan
- Creatinine
- Valine
- Potassium
|
Topics |
- Adult
- Albuminuria
(drug therapy, urine)
- Angiotensin II Type 1 Receptor Blockers
(pharmacology, therapeutic use)
- Blood Pressure
(drug effects)
- Creatinine
(blood)
- Female
- Glomerular Filtration Rate
(drug effects)
- Hematocrit
- Humans
- Kidney Transplantation
- Male
- Middle Aged
- Potassium
(blood)
- Prospective Studies
- Tetrazoles
(pharmacology, therapeutic use)
- Valine
(analogs & derivatives, pharmacology, therapeutic use)
- Valsartan
|